The median of IL-6 in the controls was 1.1 (1.12–1.76 pg/mL), significantly lower than that observed in CKD patients treated with β-blockers [14.04 (0.61–21.42) pg/mL, p = 0.005] or untreated with these drugs [19.94 (5.75–28.64) pg/mL, p < 0.001]. Here, IL6 is linked to chronic kidney disease.